Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Debt to Equity (2016 - 2024)

Protalix BioTherapeutics (PLX) has 11 years of Debt to Equity data on record, last reported at $0.71 in Q2 2024.

  • For Q2 2024, Debt to Equity changed N/A year-over-year to $0.71; the TTM value through Jun 2024 reached $0.71, changed N/A, while the annual FY2023 figure was $0.6, N/A changed from the prior year.
  • Debt to Equity reached $0.71 in Q2 2024 per PLX's latest filing, up from $0.69 in the prior quarter.
  • Across five years, Debt to Equity topped out at $15.21 in Q3 2021 and bottomed at -$2.01 in Q4 2020.
  • Average Debt to Equity over 4 years is $4.28, with a median of $0.7 recorded in 2024.